Phase 2 Osteoarthritis Trial, Recruiting NCT05839535 Sponsor: Massachusetts General Hospital Condition: Osteoarthritis
Back to Osteoarthritis

Phase 2 Osteoarthritis Trial, Recruiting

NCT05839535
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People between 45 and 75 years of age
  • People who have been diagnosed with knee osteoarthritis in one or both knees for at least the past 3 months, based on recognised classification standards
  • People who are physically able to take part in a movement and stretching program
  • People who are willing to commit to completing the full 12-week study
  • People who are able to have an MRI scan
  • People who can read and understand English, including those for whom English is a second language, as long as they feel comfortable understanding the study questionnaires

Who may not be able to join:

  • People who have regularly practised BDJ, Tai Chi, Yoga, other mind-body practices, physical therapy, or regular exercise such as running or cycling within the past year
  • People with serious health conditions that could limit their ability to take part, such as heart disease with symptoms, lung disease requiring extra oxygen, uncontrolled metabolic conditions, or severe kidney or liver disease
  • People who have had steroid injections into the affected knee joint, or reconstructive knee surgery, within the past 3 months, or hyaluronic acid injections into a joint within the past 6 months
  • People who score below 24 on a standard memory and thinking assessment called the Mini-Mental Status Examination
  • People who are unable to walk without a cane or other walking aid
  • People who are planning to have knee surgery during the study period
  • People who plan to permanently move away from the local area before the trial ends

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 617-7267893

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
5 March 2024
Est. completion
30 March 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

M1 resting state functional connectivity

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov